Individualisation of antiviral therapy for chronic hepatitis C

Journal of Gastroenterology and Hepatology (Australia)

Volumn 25, Issue 7, 2010, Pages 1206-1216

  Teoh, Narci C ^a   Farrell, Geoffrey C ^a   Chan, Henry L Y ^b  

^a Canberra Hospital   (Australia)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

chronic hepatitis C; insulin resistance; pegylated interferon; rapid viral response; ribavirin; side effects; suboptimal response

Indexed keywords

PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; ANTIVIRUS AGENT; INTERFERON; VIRUS RNA; PEGINTERFERON; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN;

CYTOPENIA; DEPRESSION; DRUG ERUPTION; GENOTYPE; HEPATITIS C; HUMAN; INSULIN RESISTANCE; LIVER CIRRHOSIS; LIVER FIBROSIS; OBESITY; PRIORITY JOURNAL; REVIEW; THYROID DISEASE; TREATMENT OUTCOME; VIRUS LOAD; BLOOD; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG MONITORING; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; PATIENT CARE; PERSONALIZED MEDICINE; TIME; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; CHRONIC HEPATITIS C; DIABETES MELLITUS; DRUG DOSE COMPARISON; HEPATITIS C VIRUS; HYPOTHYROIDISM; MULTICENTER STUDY (TOPIC); NEUTROPENIA; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; THROMBOCYTOPENIA; THYROTOXICOSIS; TREATMENT DURATION;

ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INDIVIDUALIZED MEDICINE; INTERFERONS; PATIENT CARE TEAM; RIBAVIRIN; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 77953966543     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2010.06392.x     Document Type: Review

References (92)

1. Yuen MF, Hou JL, Chutaputti A et al. Hepatocellular carcinoma in the Asian pacific region. J. Gastroenterol. Hepatol. 2009 24 : 346 353.
2. Imazeki F, Yokosuka O, Fukai K, Shasho H. Favourable prognosis of chronic hepatitis C after interferon therapy by long-term cohort study. Hepatology 2003 38 : 493 502.
3. Bruno S, Stroffolini T, Colombo M et al. Sustained virological response to interferon-a is associated with improved outcome in HVC-related Cirrhosis: a retrospective study. Hepatology 2007 45 : 579 587.
4. Ueno Y, Sollano JD, Farrell GC. Prevention of hepatocellular carcinoma complicating chronic hepatitis C. J. Gastroenterol. Hepatol. 2009 24 : 531 536.
5. McCaughan GW, Omata M, the Asian Pacific Association for the Study of the Liver (APASL) Hepatitis C Working Party. Asian Pacific Association of the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. J. Gastroenterol. Hepatol. 2007 22 : 615 633.
6. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of Hepatitis C: an Update. Hepatology 2009 49 : 1335 1374.
7. Modi AA, Hoofnagle JH. New therapies for Hepatitis C. Hepatology 2007 46 : 615 617.
8. McHutchison JG, Manns MP, Muir AJ et al. Telaprevir for previously treated chronic HCV infection. N. Engl. J. Med. 2010 362 : 1292 1298.
9. Everson GT, Hoefs JC, Seeff LB et al. Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: lessons from the HALT-C Trial. Hepatology 2006 44 : 1675 1684.
10. Khuroo MS, Khuroo MS, Dahab ST. Meta-analysis: a randomized trial of peginterferon plus ribavirin for the initial treatment of chronic hepatitis C genotype 4. Aliment. Pharmacol. Ther. 2004 20 : 931 938.
11. Yu ML, Chuang WL. Treatment of chronic hepatitis C in Asia: when East meets West. J. Gastroenterol. Hepatol. 2009 24 : 336 345.
12. Knight V, Sievert W. When less may not be best - the challenge of individualising antiviral therapy for chronic hepatitis C infection. J. Gastroenterol. Hepatol. 2009 24 : 366 371.
13. Iwasaki Y, Ikeda H, Araki Y et al. Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C. Hepatology 2006 43 : 54 63.
14. Romero-Gómez M, Del Mar Viloria M, Andrade RJ et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005 128 : 636 641.
15. Poustchi H, Negro F, Hui J et al. Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. J. Hepatol. 2008 48 : 28 34.
16. Dai CY, Huany JF, Hsieh MY et al. Insulin resistance predicts response to perginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients. J. Hepatol. 2009 50 : 712 718.
17. Tsochatzis EA, Manolakopoulos S, Papatheodoridis GV et al. Insulin resistance and metabolic syndrome in chronic liver diseases: old entities with new implications. Scand. J. Gastroenterol. 2009 44 : 6 14.
18. Mangia A, Minerva N, Bacca D et al. Determinants of relapse after a short (12 weeks) course of antiviral therapy and re-treatment efficacy of a prolonged effect in patients with chronic hepatitis C virus genotype 2 or 3 infection. Hepatology 2009 49 : 358 363.
19. Kamal SM, Samer S, Kamary E et al. Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: the role of rapid and early virologic response. Hepatology 2007 46 : 1732 1740.
20. Zekry A. Cytokines and liver injury in chronic HCV genotype 4 infection. J. Gastroenterol. Hepatol. 2009 24 : 332 335.
21. Mohamed MK. Risk factors for the development of diabetes mellitus in chronic HCV genotype 4 infection. J. Gastroenterol. Hepatol. 2009 24 : 6 8.
22. Mangia A, Andriulli A. Tailoring the length of antiviral treatment for hepatitis C. Gut 2010 59 : 1 5.
23. Davis GL, Wong JB, McHutchison JG et al. Early virologic response to treatment with peginterferon Alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003 38 : 645 652.
24. Hoefs JC, Morgan TR. Seventy-two weeks of peginterferon and ribavirin for patients with partial early virologic response? Hepatology 2007 46 : 1671 1674.
25. Sánchez-Tapias JM, Diago M, Escartin P et al. Peginterferon- alpha2a plus ribavirin for 48 versus 72 weeks in patients with detectabe hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2006 131 : 1363.
26. Kumar D, Wallington-Beddoe C, George J et al. Effectiveness of interferon alfa-2b/ribavirin combination therapy for chronic hepatitis C in a clinic setting. Med. J. Aust. 2003 178 : 267 271.
27. Chen T-M, Huang P-T, Lin C-H et al. Feasibility of individualized treatment for hepatitis C patients in the real world. J. Gastroenterol. Hepatol. 2009 25 : 61 9.
28. Neumann AU, Lam NP, Dahari H et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interfero-alpha therapy. Science 1998 282 : 103 107.
29. Zeuzem S, Lee JH, Franke A et al. Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa. Hepatology 1998 27 : 1149 1156.
30. Neumann AU, Lam NP, Dahari H et al. Differences in viral dynamics between genotypes 1 and 2 hepatitis C virus. J. Infect. Dis. 2000 182 : 28 35.
31. Fried MW, Jensen DM, Rodriguez-Torres M et al. Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin. Hepatology 2008 48 : 1033 1043.
32. Mangia A, Santoro R, Minerva N et al. Peginterferon alfa-2b and ribavirin for 12 vs 24 weeks in hepatitis C genotype 2 or 3. N. Engl. J. Med. 2005 352 : 2609 2617. (Pubitemid 41007847)
33. Dalgard O, Bjoro K, Hellman KB et al. Treatment with pegylated interferon and ribavirin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 2004 41 : 1260 1263.
34. Tarantino G, Craxi A. Optimizing the treatment of chronic hepatitis due to hepatitis C virus genotypes 2 and 3: a review. Liver Int. 2009 29 : 31 8.
35. Zeuzem S, Berg T, Moeller B et al. Expert opinion on the treatment of patients with chronic hepatitis C. J. Viral Hepat. 2009 16 : 75 90.
36. Shiffman ML, Suter F, Bacon BR et al. Peginterferon alfa-2a and ribavirin for 16 and 24 weeks in HCV genotype 2 or 3. N. Engl. J. Med. 2007 357 : 124 134.
37. Mangia A, Minerva N, Bacca D et al. Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial. Hepatology 2008 47 : 43 50.
38. Ferenci P, Laferl H, Scherzer TM et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology 2008 135 : 451 458.
39. Schiffman ML, Suter F, Bacon B et al. Peginterferon alfa-2A and ribavirin for 16 or 24 weeks in HCV genotype2 or 3. N. Engl. J. Med. 2007 357 : 124 134.
40. Diago M, Chiffman ML, Bronowicki J-P et al. Identifying hepatitis C virus genotype 2/3 patients who can receive a 16 weeks abbreviated course of peginterferon alfa-2a (40kD) plus ribavirin. Hepatology 2010 51 : 1897 1903.
41. Hanouneh IA, Feldstein AE, McCullogh AJ et al. The significance of metabolic syndrome in the setting of recurrent hepatitis C after liver transplantation. Liver Transpl. 2008 14 : 1287 1293.
42. Hui JM, Sud A, Farrell GC et al. Insulin resistance is associated with chronic hepatitis C viral infection and fibrosis progression. Gastroenterology 2003 125 : 1695 1704.
43. Moucari R, Asselah T, Cazals-Hatem D et al. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology 2008 134 : 416 423.
44. Shintani Y, Fujie H, Miyoshi H et al. Hepatitis C virus infection and diabetes: direct involvement with the virus in the development of insulin resistance. Gastroenterology 2004 126 : 840 848.
45. Knobler H, Zhornicky T, Sandler A et al. Tumor necrosis factor-alpha-induced insulin resistance may mediate the hepatitis C virus-diabetes association. Am. J. Gastroenterol. 2003 98 : 2751 2756.
46. Banerjee S, Saito K, Ait-Goughoulte M et al. Hepatitis C virus core protein upregulates serine phosphorylation of insulin receptor substrate-1 and impaired downstream akt/protein kinase B signalling pathway for insulin resistance. J. Virol. 2008 82 : 2606 2612.
47. Milner KL, van der Poorten D, Trenell M et al. Chronic hepatitis C is associated with peripheral rather than hepatic insulin resistance. Gastroenterology 2010 138 : 932 941.
48. Negro F. Correction of insulin resistance in chronic hepatitis C patients not responding to the standard of care: more questions than answers. Hepatology 2009 50 : 1267 1272.
49. Jensen D, Morgan T, Marcellin P et al. Rapid virologic response at week 4 (RVR) of peginterferon alfa2a (40KD) plus ribavirin treatment predicts sustained virological response (SVR) after 24 weeks in genotype 1 patients. Hepatology 2006 43 : 954 960.
50. Yu M-L, Dai C-Y, Huang J-F et al. Rapid virological response to peginterferon and ribavirin for hepatitis C genotype 1: the role of weight-based ribavirin exposure. Hepatology 2008 48 : 1019 1020.
51. Zeuzem S, Buti M, Ferenci P et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J. Hepatol. 2006 44 : 97 103.
52. Zeuzem S, Hultcrantz R, Bourliere M et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J. Hepatol. 2004 40 : 993 999.
53. Yu ML, Dai CY, Huang JF et al. A randomized study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 2007 56 : 553 559.
54. Dev AT, McCaw R, Sundarajan V, Bowden S et al. Southeast Asian patients with chronic hepatitis C: the impact of novel genotypes and race on treatment outcome. Hepatology 2002 36 : 1259 1265.
55. Fung J, Lai CL, Hung I et al. Chronic hepatitis C virus genotype 6 infection: response to pegylated interferon and ribavirin. J. Infect. Dis. 2008 198 : 808 812.
56. Dalgard O, Bjoro K, Ring-Larsen H et al. In patients with HCV genotype 2 or 3 infection and RVR 12 weeks treatment in noninferior to 24 weeks. Pooled analysis of two Scandinavian trials. Eur. J. Gastroenterol. Hepatol. 2010 22 : 552 556.
57. Berg T, von Wagner M, Nasser S et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon alfa-2a plus ribavirin. Gastroenterology 2006 130 : 1086 1097.
58. Chan HL, Wong VW. Can dietetic intervention for obesity ever succeed in real life? J. Gastroenterol. Hepatol. 2007 22 : 459 460.
59. Roberts SK, Weltman MD, Crawford DH et al. Impact of high-dose peginterferon alfa-2A on virological response rates in patients with hepatitis C genotype 1: a randomized controlled trial. Hepatology 2009 50 : 1045 1055.
60. Hickman IJ. Obesity management in liver clinics: what's your style of lifestyle intervention? J. Gastroenterol. Hepatol. 2009 24 : 327 328.
61. Osland EJ, Powell EE, Banks M et al. Obesity management in liver clinics: translation of research clinical practice. J. Gastroenterol. Hepatol. 2007 22 : 504 509.
62. St George A, Bauman A, Johnston A et al. Effect of a lifestyle intervention in patients with abnormal enzymes and metabolic risk factors. J. Gastroenterol. Hepatol. 2009 24 : 399 407.
63. Romero-Gómez M, Diago M, Andrade RJ et al. Treatment of insulin resistance with Metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribarivin. Hepatology 2009 50 : 1702 1708.
64. Wang CC, Kao JH. Metformin improves sustained virologic response in difficult-to-cure hepatitis C: more questions than answers. Hepatology 2010 51 : 1082 1083.
65. Dore GJ, Hellard M, Matthews GV et al. Effective treatment of injecting drug users with recently acquired hepatitis C virus infection. Gastroenterology 2010 138 : 123 135.
66. Knott A, Dieperink E, Willenbring ML et al. Integrated psychiatric/medical care in a chronic hepatitis C clinic: effect on antiviral treatment evaluation and outcomes. Am. J. Gastroenterol. 2006 101 : 2254 2262.
67. Hallinen R, Byrne A, Amin J et al. Hepatitis C virus prevalence and outcomes among injecting drug users on opioid replacement therapy. J. Gastroenterol. Hepatol. 2005 20 : 1082 1086.
68. De Bie J, Robaeys G, Buntinx F. Hepatitis C, interferon alpha and psychiatric co-morbidity intravenous drug users (IVDU): guidelines for clinical practice. Acta Gastroenterol. Belg. 2005 68 : 68 80.
69. Schaefer M, Schmidt F, Folwaczny C et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 2003 37 : 443 451.
70. Fontana RJ, Kronfol Z, Lindsay KL et al. Changes in modd states and biomarkers during peginterferon and ribavirin treatment in chronic hepatitis C. Am. J. Gastroenterol. 2008 103 : 2766 2775.
71. Patten SB. Psychiatric side effects of interferon treatment. Curr. Drug Saf. 2006 1 : 143 150.
72. Yawn BP, Rocca LG, Wollan PC. 10-year trends in the diagnosis and treatment of hepatitis C concomitant mental health disorders: 1995 to 2005. Prim Care Companion J Clin Psychiatry 2008 10 : 349 354.
73. Schaefer M, Sarkar R, Spengler U et al. Es-citalopram for the prevention of peginterferon and ribavirin associated with depression in HCV-infected patients without psychiatric risk factors (Cippad-study). Hepatology 2008 48 (Suppl 432A.
74. Evon DM, Ramcharran D, Belle SH et al. Prospective analysis of depression during perinterferon and ribavirin therapy of chronic hepatitis C: results of the viral study. Am. J. Gastroenterol. 2009 104 : 2949 2958.
75. Sockalingam S, Abbey SE. Managing depression during hepatitis C treatments. Can. J. Psychiatry 2009 54 : 614 625.
76. Alvarez-Uria G, Day JN, Nasir AJ et al. Factors associated with treatment failure of patients with psychiatric disease and injecting drug users in the treatment of genotype 2 or 3 hepatitis C chronic infection. Liver Int. 2009 29 : 1051 1055.
77. Huckans M, Mitchell A, Pavawalla S et al. The influence of antiviral therapy on psychiatric symptoms among patients with hepatitis C and schizophrenia. Antivir. Ther. 2010 15 : 111 119.
78. Dar Santos AE, Partovi N, Ford JA et al. Use of hematopoietic growth factors as adjuvant therapy for anemia and neutropenia in the treatment of hepatitis C. Ann. Pharmacother. 2007 41 : 268 275.
79. Worman HJ. Re-evaluating the use of growth factors as adjuvant treatment in chronic hepatitis C. Hepatology 2007 46 : 1307 1308.
80. Douglas T, Spivak JL. Dieterich, Hematologic disorders associated with hepatitis C virus infection and their management. Clin. Infect. Dis. 2003 37 : 533 541.
81. MacNicholas R, Norris S. Optimizing SVR and management of the haematological side effects of peginterferon/ribavirin antiviral therapy for HCV - The role of epoeitin, G-CSF and novel agents. Aliment. Pharmacol. Ther. 2010 31 : 929 937.
82. Mangia A, Dalgard O, Minerva N et al. Ribavirin dosage in HCV genotypes 2 and 3 patients completing short therapy with peg-interferon alfa-2b and ribavirin. Aliment. Pharmacol. Ther. 2010 31 : 1346 1353.
83. Wong VW-S, Cheng AY-S, Chang HL-Y. Interferon-induced thyroid dysfunction - not always transient. J. Gastroenterol. Hepatol. 2009 24 : 933 940.
84. Ha T, Reeves M, Gibson R et al. Development of thyroid diseases in the treatment of chronic hepatitis C with alpha-interferon may be a good prognostic in achieving a sustained virological response: a meta-analysis. J. Gastroenterol. Hepatol. 2009 24 : 1163 1168.
85. Charles ED, Dustin LB. Hepatitis C virus-induced cryoglubulinemia. Kidney Int. 2009 76 : 818 824.
86. Zignego AL, Craxi A. Extrahepatic manifestations of hepatitis C virus infection. Clin. Liver Dis. 2008 12 : 611 636.
87. Berk DR, Mallory SB, Keeffe EB et al. Dermatologic disorders associated with chronic hepatitis C effect on interferon therapy. Clin. Gastroenterol. Hepatol. 2007 5 : 142 151.
88. Ge D, Fellay J, Thompson AJ et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009 461 : 399 401.
89. Tanaka Y, Nishida N, Sugiyama M et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat. Genet. 2009 41 : 1105 1109.
90. Hézode C, Forestier N, Dusheiko G et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N. Engl. J. Med. 2009 360 : 1839 1850.
91. Lin C, Kwong AD, Perni RB. Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease. Infect. Disord. Drug Targets 2006 6 : 3 16.
92. McHutchison JG, Manns MP, Muir AJ et al. Telaprevir for previously treated chronic HCV infection. N. Engl. J. Med. 2010 362 : 16 47.